Shopping Cart 0
Cart Subtotal
AED 0

Irritable Bowel Syndrome - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 7340

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 14680

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 22020
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Irritable Bowel Syndrome-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Irritable Bowel Syndrome-Pipeline Review, H2 2018, provides an overview of the Irritable Bowel Syndrome (Gastrointestinal) pipeline landscape.

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder that affects large intestine (colon). Symptoms include cramping, abdominal pain, bloating gas, diarrhea, backache, muscle pains, poor appetite and constipation. These symptoms can be triggered by food, stress and hormones. Risk factors include age and family history. Treatment includes anti-diarrheal, anticholinergic, antidepressant and antibiotics medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Irritable Bowel Syndrome-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Irritable Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Irritable Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 10, 7, 1, 10 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Irritable Bowel Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome (Gastrointestinal).

- The pipeline guide reviews pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Irritable Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Irritable Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Irritable Bowel Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 5

Irritable Bowel Syndrome-Overview 6

Irritable Bowel Syndrome-Therapeutics Development 7

Irritable Bowel Syndrome-Therapeutics Assessment 15

Irritable Bowel Syndrome-Companies Involved in Therapeutics Development 23

Irritable Bowel Syndrome-Drug Profiles 34

Irritable Bowel Syndrome-Dormant Projects 113

Irritable Bowel Syndrome-Discontinued Products 117

Irritable Bowel Syndrome-Product Development Milestones 118

Appendix 127


List Of Figure

List of Figures

Number of Products under Development for Irritable Bowel Syndrome, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Irritable Bowel Syndrome, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Irritable Bowel Syndrome-Pipeline by 4D Pharma PLC, H2 2018

Irritable Bowel Syndrome-Pipeline by Allergan Plc, H2 2018

Irritable Bowel Syndrome-Pipeline by Ardelyx Inc, H2 2018

Irritable Bowel Syndrome-Pipeline by Boston Pharmaceuticals Inc, H2 2018

Irritable Bowel Syndrome-Pipeline by ConSynance Therapeutics Inc, H2 2018

Irritable Bowel Syndrome-Pipeline by Cosmo Pharmaceuticals NV, H2 2018

Irritable Bowel Syndrome-Pipeline by Dong-A ST Co Ltd, H2 2018

Irritable Bowel Syndrome-Pipeline by Eisai Co Ltd, H2 2018

Irritable Bowel Syndrome-Pipeline by Enterome Bioscience SA, H2 2018

Irritable Bowel Syndrome-Pipeline by ImmuneBiotech AB, H2 2018

Irritable Bowel Syndrome-Pipeline by Ironwood Pharmaceuticals Inc, H2 2018

Irritable Bowel Syndrome-Pipeline by Kissei Pharmaceutical Co Ltd, H2 2018

Irritable Bowel Syndrome-Pipeline by Merck & Co Inc, H2 2018

Irritable Bowel Syndrome-Pipeline by Metacrine Inc, H2 2018

Irritable Bowel Syndrome-Pipeline by Napo Pharmaceuticals Inc, H2 2018

Irritable Bowel Syndrome-Pipeline by Nextbiotix SAS, H2 2018

Irritable Bowel Syndrome-Pipeline by Protagonist Therapeutics Inc, H2 2018

Irritable Bowel Syndrome-Pipeline by RaQualia Pharma Inc, H2 2018

Irritable Bowel Syndrome-Pipeline by RedHill Biopharma Ltd, H2 2018

Irritable Bowel Syndrome-Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2018

Irritable Bowel Syndrome-Pipeline by Synthetic Biologics Inc, H2 2018

Irritable Bowel Syndrome-Pipeline by Vitality Biopharma Inc, H2 2018

Irritable Bowel Syndrome-Dormant Projects, H2 2018

Irritable Bowel Syndrome-Discontinued Products, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Irritable Bowel Syndrome Therapeutic Products under Development, Key Players in Irritable Bowel Syndrome Therapeutics, Irritable Bowel Syndrome Pipeline Overview, Irritable Bowel Syndrome Pipeline, Irritable Bowel Syndrome Pipeline Assessment


Companies

4D Pharma PLC

Allergan Plc

Ardelyx Inc

Boston Pharmaceuticals Inc

ConSynance Therapeutics Inc

Cosmo Pharmaceuticals NV

Dong-A ST Co Ltd

Eisai Co Ltd

Enterome Bioscience SA

ImmuneBiotech AB

Ironwood Pharmaceuticals Inc

Kissei Pharmaceutical Co Ltd

Merck & Co Inc

Metacrine Inc

Napo Pharmaceuticals Inc

Nextbiotix SAS

Protagonist Therapeutics Inc

RaQualia Pharma Inc

RedHill Biopharma Ltd

Sumitomo Dainippon Pharma Co Ltd

Synthetic Biologics Inc

Vitality Biopharma Inc

Irritable Bowel Syndrome-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Irritable Bowel Syndrome-Pipeline Review, H2 2018, provides an overview of the Irritable Bowel Syndrome (Gastrointestinal) pipeline landscape.

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder that affects large intestine (colon). Symptoms include cramping, abdominal pain, bloating gas, diarrhea, backache, muscle pains, poor appetite and constipation. These symptoms can be triggered by food, stress and hormones. Risk factors include age and family history. Treatment includes anti-diarrheal, anticholinergic, antidepressant and antibiotics medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Irritable Bowel Syndrome-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Irritable Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Irritable Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 10, 7, 1, 10 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Irritable Bowel Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome (Gastrointestinal).

- The pipeline guide reviews pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Irritable Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Irritable Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Irritable Bowel Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents 2

Introduction 5

Irritable Bowel Syndrome-Overview 6

Irritable Bowel Syndrome-Therapeutics Development 7

Irritable Bowel Syndrome-Therapeutics Assessment 15

Irritable Bowel Syndrome-Companies Involved in Therapeutics Development 23

Irritable Bowel Syndrome-Drug Profiles 34

Irritable Bowel Syndrome-Dormant Projects 113

Irritable Bowel Syndrome-Discontinued Products 117

Irritable Bowel Syndrome-Product Development Milestones 118

Appendix 127


List Of Figure

List of Figures

Number of Products under Development for Irritable Bowel Syndrome, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Irritable Bowel Syndrome, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Irritable Bowel Syndrome-Pipeline by 4D Pharma PLC, H2 2018

Irritable Bowel Syndrome-Pipeline by Allergan Plc, H2 2018

Irritable Bowel Syndrome-Pipeline by Ardelyx Inc, H2 2018

Irritable Bowel Syndrome-Pipeline by Boston Pharmaceuticals Inc, H2 2018

Irritable Bowel Syndrome-Pipeline by ConSynance Therapeutics Inc, H2 2018

Irritable Bowel Syndrome-Pipeline by Cosmo Pharmaceuticals NV, H2 2018

Irritable Bowel Syndrome-Pipeline by Dong-A ST Co Ltd, H2 2018

Irritable Bowel Syndrome-Pipeline by Eisai Co Ltd, H2 2018

Irritable Bowel Syndrome-Pipeline by Enterome Bioscience SA, H2 2018

Irritable Bowel Syndrome-Pipeline by ImmuneBiotech AB, H2 2018

Irritable Bowel Syndrome-Pipeline by Ironwood Pharmaceuticals Inc, H2 2018

Irritable Bowel Syndrome-Pipeline by Kissei Pharmaceutical Co Ltd, H2 2018

Irritable Bowel Syndrome-Pipeline by Merck & Co Inc, H2 2018

Irritable Bowel Syndrome-Pipeline by Metacrine Inc, H2 2018

Irritable Bowel Syndrome-Pipeline by Napo Pharmaceuticals Inc, H2 2018

Irritable Bowel Syndrome-Pipeline by Nextbiotix SAS, H2 2018

Irritable Bowel Syndrome-Pipeline by Protagonist Therapeutics Inc, H2 2018

Irritable Bowel Syndrome-Pipeline by RaQualia Pharma Inc, H2 2018

Irritable Bowel Syndrome-Pipeline by RedHill Biopharma Ltd, H2 2018

Irritable Bowel Syndrome-Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2018

Irritable Bowel Syndrome-Pipeline by Synthetic Biologics Inc, H2 2018

Irritable Bowel Syndrome-Pipeline by Vitality Biopharma Inc, H2 2018

Irritable Bowel Syndrome-Dormant Projects, H2 2018

Irritable Bowel Syndrome-Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Irritable Bowel Syndrome Therapeutic Products under Development, Key Players in Irritable Bowel Syndrome Therapeutics, Irritable Bowel Syndrome Pipeline Overview, Irritable Bowel Syndrome Pipeline, Irritable Bowel Syndrome Pipeline Assessment


Companies

4D Pharma PLC

Allergan Plc

Ardelyx Inc

Boston Pharmaceuticals Inc

ConSynance Therapeutics Inc

Cosmo Pharmaceuticals NV

Dong-A ST Co Ltd

Eisai Co Ltd

Enterome Bioscience SA

ImmuneBiotech AB

Ironwood Pharmaceuticals Inc

Kissei Pharmaceutical Co Ltd

Merck & Co Inc

Metacrine Inc

Napo Pharmaceuticals Inc

Nextbiotix SAS

Protagonist Therapeutics Inc

RaQualia Pharma Inc

RedHill Biopharma Ltd

Sumitomo Dainippon Pharma Co Ltd

Synthetic Biologics Inc

Vitality Biopharma Inc